Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review
What this study found
Overall, vitamin K supplementation reduced dp-ucMGP but did not reliably slow vascular calcification progression. In the included intervention studies, dp-ucMGP rose with increasing aortic calcification severity in hemodialysis patients, but the baseline calcification score did not correlate with the subsequent dp-ucMGP drop. In CKD stages 3-5, there was no difference in coronary CAC progression between MK-7 plus cholecalciferol and comparator treatment, and CAC still increased despite MK-4 treatment; in postmenopausal women, neither baseline nor change in MGP concentrations predicted CAC…
- Study & population
- Systematic review of observational studies and randomized trials examining circulating matrix Gla protein fractions and vascular calcification.
- Intervention
- Included interventional studies evaluated vitamin K regimens across several populations: MK-7 360 µg once daily in hemodialysis patients; MK-7 90 µg plus cholecalciferol 10 µg in non-dialyzed CKD stages 3-5; MK-4 15 mg three times daily plus cholecalciferol 10 µg in cardiovascular disease; and phylloquinone 500 µg…
- Key limitation
- The evidence was highly heterogeneous in calcification territory, MGP fraction measured, populations, and study design.
Original abstract
Specific patient cohorts are at increased risk of vascular calcification. Functional matrix-gla protein (MGP), a tissue-derived vitamin K dependent protein, is reported to be an important inhibitor of vascular calcification and may have clinical potential to modify the progression of vascular calcification through regulation of functional MGP fractions. This systematic review examines twenty-eight studies which assess the relationship between circulating protein expressions of MGP species and vascular calcification in different arterial beds. The included studies examined participants with atherosclerosis, chronic kidney disease (CKD), diabetes, healthy participants, vitamin K supplementation, measured plasma vitamin K levels and vitamin K antagonist usage. The current review reports conflicting results regarding MGP fractions with respect to local calcification development indicating that a multifaceted relationship exists between the MGP and calcification. A primary concern regarding the studies in this review is the large degree of variability in the calcification location assessed and the fraction of MGP measured. This review suggests that different underlying molecular mechanisms can accelerate local disease progression within the vasculature, and specific circulating fractions of MGP may be influenced differently depending on the local disease states related to vascular calcification development. Further studies examining the influence of non-functional MGP levels, with respect to specific calcified arterial beds, are warranted.